GSK Pharmaceuticals Reports Q2 FY27 Consolidated Results and Leadership Changes
GlaxoSmithKline Pharmaceuticals Ltd · Change in Auditor · 04 Nov 2026, 12:31 am
GSK Pharmaceuticals Reports Q2 FY27 Consolidated Results and Leadership Changes GlaxoSmithKline Pharmaceuticals reported consolidated revenue from operations of ₹1,183.57 crore for the quarter ended 30th Sep'26, up 20.78% YoY from ₹979.94 crore. Consolidated net profit rose 30.44% YoY to ₹335.88 crore, supported by other income of ₹72.78 crore (including ₹42.09 crore interest on tax refund). Diluted EPS stood at ₹19.83. Additionally, the board approved the appointment of Sandeep Seth as Head – Ethics & Compliance and proposed Walker Chandiok & Co LLP as Statutory Auditors for five years starting FY28.
Original exchange filing (PDF)
More announcements from GlaxoSmithKline Pharmaceuticals Ltd
- As per attachment · 08 Nov 2026
- As per attachment · 05 Nov 2026
- As per attachment · 05 Nov 2026
- Analyst meet Presentation · 04 Nov 2026
- As per attachment · 04 Nov 2026
- As per attachment · 04 Nov 2026
- outcome of Meeting · 04 Nov 2026
- GlaxoSmithKline Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 04 Nov 2026
